Advances in the Treatment of Rheumatoid Arthritis: Costs and Challenges.
Publication
, Journal Article
Pisetsky, DS
Published in: N C Med J
2017
Rheumatoid arthritis is the most common form of inflammatory arthritis. Because of advances in therapy, clinical outcomes have improved dramatically and remission is possible for many patients. These advances have come with many challenges, prompting consideration of strategies to improve diagnosis and treatment and implement more cost-effective care.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
N C Med J
DOI
ISSN
0029-2559
Publication Date
2017
Volume
78
Issue
5
Start / End Page
337 / 340
Location
United States
Related Subject Headings
- Humans
- Cost-Benefit Analysis
- Biosimilar Pharmaceuticals
- Arthritis, Rheumatoid
- Antirheumatic Agents
- 42 Health sciences
- 32 Biomedical and clinical sciences
- 11 Medical and Health Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Pisetsky, D. S. (2017). Advances in the Treatment of Rheumatoid Arthritis: Costs and Challenges. N C Med J, 78(5), 337–340. https://doi.org/10.18043/ncm.78.5.337
Pisetsky, David S. “Advances in the Treatment of Rheumatoid Arthritis: Costs and Challenges.” N C Med J 78, no. 5 (2017): 337–40. https://doi.org/10.18043/ncm.78.5.337.
Pisetsky DS. Advances in the Treatment of Rheumatoid Arthritis: Costs and Challenges. N C Med J. 2017;78(5):337–40.
Pisetsky, David S. “Advances in the Treatment of Rheumatoid Arthritis: Costs and Challenges.” N C Med J, vol. 78, no. 5, 2017, pp. 337–40. Pubmed, doi:10.18043/ncm.78.5.337.
Pisetsky DS. Advances in the Treatment of Rheumatoid Arthritis: Costs and Challenges. N C Med J. 2017;78(5):337–340.
Published In
N C Med J
DOI
ISSN
0029-2559
Publication Date
2017
Volume
78
Issue
5
Start / End Page
337 / 340
Location
United States
Related Subject Headings
- Humans
- Cost-Benefit Analysis
- Biosimilar Pharmaceuticals
- Arthritis, Rheumatoid
- Antirheumatic Agents
- 42 Health sciences
- 32 Biomedical and clinical sciences
- 11 Medical and Health Sciences